002287.SZ SHZ
Tibet Cheezheng Tibetan Medicine Co., Ltd.
1W: -1.7%
1M: -3.8%
3M: -1.6%
YTD: -22.1%
1Y: -32.9%
3Y: -11.1%
5Y: -20.1%
¥19.38 ($2.89)
+0.26 (+1.36%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$2.4B
+3.3% ▲
5Y CAGR: +10.2%
Gross Profit
$2.4B
+25.9% ▲
5Y CAGR: +13.8%
Operating Income
$763M
+16.1% ▲
5Y CAGR: +10.9%
Net Income
$646M
+11.0% ▲
5Y CAGR: +9.9%
EPS (Diluted)
$1.19
+8.2% ▲
5Y CAGR: +9.3%
EBITDA
$842M
+3.4% ▲
5Y CAGR: +16.3%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1.8B | $2.0B | $2.0B | $2.3B | $2.4B |
| YoY Growth | +19.2% | +15.5% | +0.0% | +14.3% | +3.3% |
| Cost of Revenue | $270M | $326M | $325M | $420M | $0 |
| Gross Profit | $1.5B | $1.7B | $1.7B | $1.9B | $2.4B |
| Gross Margin | 84.8% | 84.1% | 84.1% | 82.1% | 100.0% |
| R&D Expenses | $71M | $47M | $51M | $60M | $0 |
| SG&A Expenses | $986M | $1.1B | $1.2B | $1.3B | $0 |
| Operating Expenses | $711M | $1.2B | $1.1B | $1.3B | $1.7B |
| Operating Income | $790M | $522M | $646M | $657M | $763M |
| Operating Margin | 44.6% | 25.5% | 31.6% | 28.1% | 31.6% |
| Interest Expense | $56M | $56M | $67M | $60M | $0 |
| Income Before Tax | $788M | $519M | $644M | $646M | $734M |
| Tax Expense | $77M | $50M | $65M | $65M | $88M |
| Net Income | $716M | $473M | $581M | $582M | $646M |
| Net Margin | 40.4% | 23.1% | 28.4% | 24.9% | 26.7% |
| EPS (Diluted) | $1.35 | $0.89 | $1.10 | $1.10 | $1.19 |
| EBITDA | $477M | $604M | $553M | $645M | $842M |
| Shares Outstanding | 529M | 530M | 530M | 530M | 544M |